Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
iwCAR-T 2024
The 6th International Workshop on CAR-T
19–21 April 2024 | Miami, FL
Expert-led presentations and roundtable discussions from iwCAR-T 2024, covering CAR-T and immunotherapies for hematological malignancies.
iwCAR-T 2024 was supported by: Johnson & Johnson, Kite Pharma, Arcellx, Autolus, BMS, Caribou Biosciences, Genentech, Kyverna, Legend Biotech, Nkarta, Novartis and A2 Bio. Supporters have no influence over the production of content.
Explore roundtable discussions from iwCAR-T
View all videos
Scientific challenges and new approaches
CD83 as a target for hematologic malignancies
Marco Davila Roswell Park, Buffalo, NY, United States
Towards in vivo manufacturing of CAR-T
Saar Gill Perelman School of Medicine, Philadelphia, PA, United States
Long term toxicities of CAR T-cell therapy
Hematologic toxicity ("ICAHT")
Kai Rejeski LMU Munich, Munich, Germany
Secondary malignancies
Saurabh Dahiya Stanford Medicine, Stanford, CA, United States
CAR19 drives expansion of clonal hematopoiesis and associated cytopenias
Mark Hamilton Stanford Medicine, Stanford, CA, United States
New data on TCL after CAR-T
Mark Hamilton Stanford Medicine, Stanford, CA, United States
Access and point-of-care in pediatric cancer
CAR-pooling: Innovative strategies in pediatric CAR T-cell development
Nirali Shah National Cancer Institute Center for Cancer Research, Bethesda, MD, United States
Accelerating pediatric CAR T-cell orogress
Claudia Rössig University of Münster, Münster, Germany
CAR-T in CLL
Update on TRANSCEND – liso-cel in CLL/SLL
Tanya Siddiqi City of Hope, Duarte, CA, United States
Mechanisms of resistance to CAR T-cells in CLL
Saar Gill Perelman School of Medicine, Philadelphia, PA, United States
Allo approaches
Next-gen allo approaches/ donor T-cell cloaking to avoid host rejection
Sattva Neelapu The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Updates for ALLO-647/501 in R/R LBCL and FL
Frederick Locke Moffitt Cancer Center, Tampa, FL, United States
Updates for allo CAR-T PBCAR0191
Bijal Shah Moffitt Cancer Center, Tampa, FL, United States
CRISPR-edited allogeneic anti-CD19 CAR T-cell therapy for R/R B-cell NHL
Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States
iPSC derived CAR NK cells in lymphoma
Krish Patel Sarah Cannon Research Institute, Nashville, TN, United States
Allogeneic CAR NK cells in adults with AML or MDS
May Daher MD Anderson Cancer Center, Houston, TX, United States
CAR-T in ALL
Brexucabtagene autoleucel for adult ALL
Bijal Shah Moffitt Cancer Center, Tampa, FL, United States
Obe-cel updates and future directions
Claire Roddie University College London, London, United Kingdom
Anti-CD7 Allogeneic CAR T-cells in R/R T-cell ALL/LBL
Shannon Maude The Children’s Hospital of Philadelphia, Philadelphia, PA, United States
SCRI-CAR19 with CD19 T-APC to prolong CAR T-cell persistence
Rebecca Gardner St. Jude Children's Research Hospital, Memphis, TN, United States
CAR-T in multiple myeloma
CAR-T for patients with R/R myeloma: real-world experience
Doris Hansen Moffitt Cancer Center, Tampa, FL, United States
Real-world evidence of bispecific antibodies for myeloma
Yi Lin Mayo Clinic, Rochester, MN, United States
Race to the front line: CAR-T
Krina Patel The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Race to the front line: BsAbs
Larry Anderson UT Southwestern Medical Center, Dallas, TX, United States
Mechanisms of resistance: CAR-T
Damian Green Sylvester Comprehensive Cancer Center, Miami, FL, United States
Mechanisms of resistance: BsAbs
Adam Sperling Dana-Farber Cancer Institute, Boston, MA, United States
Novel CAR-T and NextGen bispecific antibodies
BCMA-directed CAR T-cell therapy anitocabtagene autoleucel
Matthew Frigault Massachusetts General Hospital, Boston, MA, United States
Updates for GPRC5D CARs in multiple myeloma
Susan Bal University of Alabama, Birmingham, AL, United States
New BsAb research and opportunities in myeloma
Sridevi Rajeeve Memorial Sloan Kettering Cancer Center, New York City, NY, United States
CAR T-cells for autoimmune diseases
Advances in CAR-T for auto-immune diseases
David Porter University of Pennsylvania, Philadelphia, PA, United States
YTB323 in severe, refractory systemic lupus erythmatosus
Pere Barba Vall d’Hebron University Hospital, Barcelona, Spain
Anti-CD19 CAR T-cell therapy (KYV-101) for myasthenia gravis
Jeremias Motte Ruhr University Bochum, Bochum, Germany
CAR-Tregs for autoimmunity
Matteo Doglio San Raffaele Hospital, Milan, Italy
Expanding the CAR platform for non-Hodgkin lymphoma
Long-term lymphoma outcomes following CAR-T cell therapy
Michael Jain Moffitt Cancer Center, Tampa, FL, United States
ZUMA-22 and ZUMA-23 axi-cel updates
Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States
New data in liso-cel – FL/MZL and MCL
Jeremy Abramson Massachusetts General Hospital Cancer Center, Boston, MA, United States
Bispecifics for lymphoma
RWD and trials in progress for epcoritamab
Krish Patel Sarah Cannon Research Institute, Nashville, TN, United States
Glofitamab RWD and trials in progress
Tycel Phillips City of Hope, Duarte, CA, United States
Total therapy for LBCL combining mosun/pola/axi-cel
Jay Spiegel University of Miami, Miami, FL, United States
Optimizing treatment through BsAbs sequencing
Gloria Iacoboni Vall d’Hebron Institute of Oncology, Barcelona, Spain
Next-generation CARs for lymphoma
CRG-022, CD22 CAR T-cell therapy for R/R LBCL after CD19 CAR-T
Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States
Bispecific CAR20.19 T-cells in MCL
Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States
CD20-targeted auto CAR-T for indolent lymphoma
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Low-dose CD19 1XX CAR with calibrated signaling in large-cell lymphoma
Jae Park Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
CAR-T in AML
AML targets and translational updates
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Mechanisms of resistance in AML
Anand Bhagwat Children's Hospital of Philadelphia, Philadelphia, PA, United States
CAR-T in pediatric AML
Nirali Shah National Cancer Institute Center for Cancer Research, Bethesda, MD, United States
iwCAR-T 2024 was supported by:
